| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/25/2002 | WO2002032933A1 Endothelin antagonist |
| 04/25/2002 | WO2002032932A2 Urotensin-ii agonists and antagonists |
| 04/25/2002 | WO2002032921A1 Antisense modulation of apaf-1 expression |
| 04/25/2002 | WO2002032897A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 04/25/2002 | WO2002032888A1 Substituted dipeptides as growth hormone secretagogues |
| 04/25/2002 | WO2002032874A2 Substituted heterocyclic compounds for treating multidrug resistance |
| 04/25/2002 | WO2002032864A1 Pharmaceutically active sulfanilide derivatives |
| 04/25/2002 | WO2002032463A1 Methods of treating cancers by stimulating dendritic cells or lymphomas with certain tnf molecules |
| 04/25/2002 | WO2002032461A2 Protein c or activated protein c-like molecules |
| 04/25/2002 | WO2002032457A1 Immunologic activities of rhesus cytomegalovirus encoded il-10 and human cytomegalovirus encoded il-10 |
| 04/25/2002 | WO2002032456A1 Remedies or preventives for rheumatoid arthritis |
| 04/25/2002 | WO2002032451A1 Vaccine composition comprising an antigen and a peptide having adjuvant properties |
| 04/25/2002 | WO2002032449A2 Method for treating ischemic events affecting the central nervous system |
| 04/25/2002 | WO2002032448A1 Remedies for obesity and obesity-associated diseases and method of evaluating these remedies |
| 04/25/2002 | WO2002032447A2 Cell damage inhibitor |
| 04/25/2002 | WO2002032446A2 Use of neutrophil inhibitory factor in combination with other thrombolytic or neuroprotective drugs for treating pathophysiological conditions involving neutrophils |
| 04/25/2002 | WO2002032445A2 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof |
| 04/25/2002 | WO2002032418A1 Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis |
| 04/25/2002 | WO2002032414A2 Ribavirin-pegylated interferon alfa hcv combination therapy |
| 04/25/2002 | WO2002032397A2 Electroprocessing in drug delivery and cell encapsulation |
| 04/25/2002 | WO2002032376A2 Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| 04/25/2002 | WO2002032374A2 Methods for treating il-18 mediated disorders |
| 04/25/2002 | WO2002032283A2 Methods of and pharmaceutical compositions for improving implantation of embryos |
| 04/25/2002 | WO2001098506A3 Methods and means for regulation of gene expression |
| 04/25/2002 | WO2001096873A3 Method for identifying apoptosis-modified proteins |
| 04/25/2002 | WO2001096366A3 Dipeptide inhibitors for the blood-clotting factor xa |
| 04/25/2002 | WO2001094392A3 Recombinant subunit proteins from porcine parvovirus produced in plants |
| 04/25/2002 | WO2001094387A3 Epididymis-specific proteins with fibronectin type ii modules |
| 04/25/2002 | WO2001093847A3 Compositions, kits, and methods for promoting defined health benefits |
| 04/25/2002 | WO2001093833A3 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 04/25/2002 | WO2001093831A3 Low carbohydrate compositions, kits thereof, and methods of use |
| 04/25/2002 | WO2001092340A3 Use of interleukin-4 antagonists and compositions thereof |
| 04/25/2002 | WO2001090320A3 A novel helicase family member and uses thereof |
| 04/25/2002 | WO2001088122A3 Erg modulators |
| 04/25/2002 | WO2001085782A3 Fusion receptor from TNF family |
| 04/25/2002 | WO2001083740A3 Splice-region antisense composition and method |
| 04/25/2002 | WO2001082874A3 A medicinal aerosol formulation |
| 04/25/2002 | WO2001081538A3 A novel polypeptide, a human connexin 9 and the polynucleotide encoding the polypeptide |
| 04/25/2002 | WO2001081536A3 A novel polypeptide, a human ysk1 kinase protein 10, and the polynucleotide encoding the polypeptide |
| 04/25/2002 | WO2001080897A3 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
| 04/25/2002 | WO2001079473A3 21953, a human prolyl oligopeptidase family member and uses thereof |
| 04/25/2002 | WO2001077309A3 Crystallization and structure determination of staphylococcus aureus thioredoxin reductase |
| 04/25/2002 | WO2001076617A3 Oral tolerance induction by collagen to prevent allograft rejection |
| 04/25/2002 | WO2001074853A3 Methods and products for regulating cell motility |
| 04/25/2002 | WO2001072957A3 Fibroblast growth factor-like molecules and uses thereof |
| 04/25/2002 | WO2001072831A3 Immunoregulator |
| 04/25/2002 | WO2001072782A3 Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| 04/25/2002 | WO2001072776A3 Agent and method for reducing intraocular pressure |
| 04/25/2002 | WO2001068880A3 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
| 04/25/2002 | WO2001062927A3 Polypeptides and corresponding polynucleotides for diagnostics and therapeutics |
| 04/25/2002 | WO2001062922A3 Polypeptides and corresponding molecules for disease detection and treatment |
| 04/25/2002 | WO2001062908A3 Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
| 04/25/2002 | WO2001062300A3 Caspase activated prodrugs therapy |
| 04/25/2002 | WO2001061010A3 GTPASE activating proteins |
| 04/25/2002 | WO2001060848A3 Conjugates targeted to target receptors |
| 04/25/2002 | WO2001059102A3 Nucleozymes with endonuclease activity |
| 04/25/2002 | WO2001058891A3 Piperazine and piperidine derivatives for treatment or prevention of neuronal damage |
| 04/25/2002 | WO2001057184A3 Use of platelet activity modulators for inhibiting complement activation |
| 04/25/2002 | WO2001056593A3 Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
| 04/25/2002 | WO2001052904A3 Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides |
| 04/25/2002 | WO2001047951A3 Angiopoietin analogs |
| 04/25/2002 | WO2001047533A3 INHIBITION OF GSK-3$g(b) |
| 04/25/2002 | WO2001042471A3 Polypeptides and polynucleotides encoding same |
| 04/25/2002 | WO2001041810A3 Nucleic acid delivery system |
| 04/25/2002 | WO2001041781A3 Id protein inhibitors for treating ocular diseases |
| 04/25/2002 | WO2001029193A3 Cell constructs that are suitable for immunotherapy, the production and the use thereof |
| 04/25/2002 | WO2000029622A3 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 04/25/2002 | US20020049422 Homeopathic preparations |
| 04/25/2002 | US20020049404 Fas ligand expressing antigen presenting cells for tolerance induction |
| 04/25/2002 | US20020049311 Novel rnase p |
| 04/25/2002 | US20020049306 Differentiation-suppressive polypeptide |
| 04/25/2002 | US20020049303 Enzymatic polypeptide for use as model for treatment of alzheimer's disease |
| 04/25/2002 | US20020049301 For therapy of cancer, diabetes, obesity, diseases of the central nervous system, inflammatory disorders, autoimmune dieseases cardiovascular diseases, for generating antibodies |
| 04/25/2002 | US20020049300 Enzymatic proteins for use in diagnosis and treatment of immune response defects |
| 04/25/2002 | US20020049236 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| 04/25/2002 | US20020049231 S(-)-3-aminothalidomide; treating wide variety of diseases including diabetic retinopathy |
| 04/25/2002 | US20020049196 Hexahydro-pyrazolo-(4,3-c)pyridine derivatives useful for increasing the endogenous production or release of growth hormone in a human or other animal, thus treat or prevent osteoporosis |
| 04/25/2002 | US20020049190 Useful in binding nitric oxide; inhibiting tumor growth |
| 04/25/2002 | US20020049185 Malonic acid based matrix metalloproteinase inhibitors |
| 04/25/2002 | US20020049183 Phospholipids, espeically phosphatidylethanolamines, covalently bound to physiologically acceptable monomers or polymers. |
| 04/25/2002 | US20020049180 KIAA0175 inhibitor is selected from the group consisting of an anti-sense molecule, a ribozyme, an antibody, an antibody fragment, a protein, a polypeptide and a small molecule. |
| 04/25/2002 | US20020049178 Injecting a nucleic acid construct encoding a neurotrophic factor into a subject's brain. |
| 04/25/2002 | US20020049177 Detecting an aberrant level or bioactivity of or screening for a Wnt pathway component or a frizzled related protein gene product |
| 04/25/2002 | US20020049175 Decreasing viral replication in cells by decreasing levels of functional cellular protease; exposing the cells to a compound which decreases cellular protease gene expression. |
| 04/25/2002 | US20020049174 First region is available for hybridization and the second region is temporarily masked. |
| 04/25/2002 | US20020049173 Binding to said target an antisense compound which is specifically hybridizable with said mRNA target and which does not elicit cleavage of the mRNA target upon binding |
| 04/25/2002 | US20020049164 Prodrugs of DP IV-inhibitors |
| 04/25/2002 | US20020049162 Methods for inhibiting smooth muscle cell proliferation |
| 04/25/2002 | US20020049161 Especially Fe(III) saccharate and gluconate; treatment of hemodialysis patients. |
| 04/25/2002 | US20020049160 Identifying an agent that increases an N-Methyl-D-Aspartate (NMDA) receptor mediated response in a neuron to an agonist |
| 04/25/2002 | US20020049159 Methods and compositions for the treatment of motor neuron injury and neuropathy |
| 04/25/2002 | US20020049158 Increasing bioavailability of a drug which is not readily absorbed in the digestive tract |
| 04/25/2002 | US20020049157 Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
| 04/25/2002 | US20020049154 Bioconjugates and delivery of bioactive agents |
| 04/25/2002 | US20020049153 Modified peptides capable of forming covalent bonds with one or more blood components, especially albumin, to form a conjugate; administered to treat humans with diabetes |
| 04/25/2002 | US20020049151 Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors |
| 04/25/2002 | US20020048816 Genetically engineered cell; for use as a vaccine; for use in screening polypeptides and antigens; for use as a support for immobilizing an enzyme, peptide or antigen |
| 04/25/2002 | US20020048815 Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression |
| 04/25/2002 | US20020048813 Methods and products for regulating cell motility |
| 04/25/2002 | US20020048812 Isolation and in vitro differentiation of conditionally immortalized murine olfactory receptor neurons |